Skip to main content

Table 1 Regression analysis for the outcomes after PS matching

From: Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study

 

Outcomes

Hazard ratio (HR) (95%CI)

P-value$

Control

Zinc

P-value^^

In-hospital mortality, n (%)§

32 (40.0)

23 (28.4)

0.12

0.64 (0.37, 1.10)

0.11

30-day mortality, n (%)§

31 (38.8)

19 (23.2)

0.03

0.52 (0.29, 0.92)

0.03

   

P-value^

beta coefficient (estimates) (95%CI)

P-value$*

Ventilator free days, Median (Q1, Q3)§

0.0 (0.00, 26.00)

20.0 (0.00, 28.00)

0.02

0.33 (− 0.21, 0.87)

0.22

ICU Length of Stay (Days), Median (Q1, Q3)&

8.0 (5.00, 15.00)

10.0 (6.00, 15.00)

0.28

0.10 (− 0.16, 0.36)

0.46

Hospital Length of Stay (Days), Median (Q1, Q3)&

16.0 (10.00, 28.00)

17.0 (12.00, 29.00)

0.61

0.03 (− 0.21, 0.27)

0.79

  1. §Denominator of the percentage is the total number of patients
  2. &Denominator is patients who survived
  3. ^^Chi-square test is used to calculate the P-value
  4. ^Wilcoxon rank sum test is used to calculate the P-value
  5. $Cox proportional hazards regression analysis is used to calculate hazard ratio (HR) and p-value
  6. $*Generalized linear model is used to calculate beta coefficient (estimates) and p-value
Back to article page

Critical Care

ISSN: 1364-8535